Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference

WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen's continued execution toward a scalable, established, multi-program cell therapy development organization.

In 2025, Tevogen advanced its proprietary ExacTcell™ platform, expanded its cytotoxic T lymphocyte (CTL) pipeline across multiple viral and oncology indications, and advanced its strategy to establish in-house GMP cell therapy manufacturing capabilities.

Platform Scalability and Manufacturing Readiness:

Tevogen reported enhancements to ExacTcell™ that increased laboratory yields of target-specific CTLs per product, supporting improved consistency and throughput. These improvements are intended to enable efficient clinical supply and support future clinical and commercial manufacturing across multiple programs using shared infrastructure.

Pipeline Expansion Across Multiple Indications:

Building on its SARS-CoV-2 proof-of-concept clinical experience, Tevogen completed T cell target identification for five additional HLA restrictions, significantly expanding potential patient coverage for its SARS-CoV-2-specific CTL product.

Tevogen also advanced target discovery and preclinical activities supporting CTL therapies addressing:

• Epstein-Barr virus (EBV) associated lymphomas
• Chronic hepatitis B, including programs focused on prevention of virus-associated hepatic diseases and cancer
• Human Papilloma Virus (HPV) related cancers
  
  
  
   

Target discovery efforts were supported by Tevogen.AI, the Company's advanced analytics division, which, among its broader analytical capabilities, supports peptide target identification, refinement, and prioritization across CTL programs.